Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma

ABSTRACT: Abstract

Background

Targeted therapies have substantially improved survival in cancer patients with malignancies outside the brain. Whether in-depth analysis for molecular alterations may also offer therapeutic avenues in primary brain tumors remains unclear. We herein present our institutional experience for glioma patients discussed in our interdisciplinary molecular tumor board (MTB) implemented at the Comprehensive Cancer Center Munich (LMU).

Methods

We retrospectively searched the database of the MTB for all recurrent glioma patients after previous therapy. Recommendations were based on next-generation sequencing results of individual patient’s tumor tissue. Clinical and molecular information, previous therapy regimens, and outcome parameters were collected.

Resu

SUBMITTER:  

PROVIDER: S-EPMC10243988 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature